Hudson Bay Capital Management LP Krystal Biotech, Inc. Transaction History

Hudson Bay Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$40.64 - $61.38 $914,400 - $1.38 Million	-22,500 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$37.76 - $48.49 $472,000 - $606,125	-12,500 Reduced 35.71%	22,500 $969,000
Q2 2020 Aug 12, 2020	BUY	$37.03 - $60.0 $1.3 Million - $2.1 Million	35,000 New	35,000 $1.45 Million

309

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.02B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.